Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 153 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo - first 24 weeks Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Exogenous Ketones on Indices of Keto-Adaptation in Obese Subjects on Weight Reducing Diets.

NCT06449287
View directory record Official record
Conditions
Ketogenic Diet, Weight Loss
Interventions
Diet, Blood Draw, Ketone/Glucose Monitoring, Body Composition, Urine Analysis, Neuropsychological Measures - ANAM
Other · Biological · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 2, 2026, 4:06 PM EDT
Active, not recruiting Phase 4 Interventional

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

NCT03953300
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

NCT02312934
View directory record Official record
Conditions
Chemo Brain, Chemotherapy-related Cognitive Impairment, Chemo Fog, Breast Cancer, Chemobrain
Interventions
Transdermal nicotine, Placebo Transdermal Patch
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
35 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 2, 2026, 4:06 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634
View directory record Official record
Conditions
Myositis
Interventions
Nipocalimab, Placebo, Glucocorticoids
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

NCT00689728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
LY2127399, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Birmingham, Alabama • Mesa, Arizona • Palm Desert, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 2, 2026, 4:06 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

NCT06364228
View directory record Official record
Conditions
Stress
Interventions
Placebo, Oxytocin Intranasal Spray 12 International Unit (12IU), Oxytocin Intranasal Spray 24 International Unit (24IU), Functional MRI
Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

NCT06726265
View directory record Official record
Conditions
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed, pembrolizumab (KEYTRUDA®), Placebo
Biological · Drug · Other
Lead sponsor
Immutep S.A.S.
Industry
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Louisville, Kentucky • Albuquerque, New Mexico • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 2 Interventional

Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

NCT05498181
View directory record Official record
Conditions
Hemodialysis
Interventions
Sacubitril-valsartan, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Collagen Vitamin C Dose Response Performance

NCT03293004
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Hydrolyzed collagen, Vitamin C, Optimized Hydrolyzed Collagen and Vitamin C, Gummy Placebo
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 2, 2026, 4:06 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

NCT03838484
View directory record Official record
Conditions
Schizophrenia, Impulsive Behavior
Interventions
Nicotine Patch, 7 Mg/24 Hr, Placebo patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

NCT01345175
View directory record Official record
Conditions
Rectal Cancer
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3502970 in Healthy Participants

NCT03929744
View directory record Official record
Conditions
Healthy
Interventions
LY3502970, Placebo, Atorvastatin, Simvastatin, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Results available

Attenuation of Corticosteroid Induced Hippocampal Changes

NCT01656187
View directory record Official record
Conditions
Organic Memory Impairment
Interventions
Memantine 10 mg capsule, Memantine-matched Placebo capsule
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Bryostatin Treatment of Moderately Severe Alzheimer's Disease

NCT04538066
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Bryostatin 1, Placebo
Drug · Other
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Colton, California • San Diego, California • Atlantis, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Variability and Irritability During the Menopause Transition

NCT05388656
View directory record Official record
Conditions
Menopause, Irritable Mood
Interventions
Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo, Progesterone 200 mg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 59 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy

NCT01517880
View directory record Official record
Conditions
GNE Myopathy, Hereditary Inclusion Body Myopathy
Interventions
Sialic Acid Extended Release (SA-ER), Placebo
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis

NCT03401229
View directory record Official record
Conditions
Nasal Polyposis
Interventions
Benralizumab 30 mg SC + Mometasone Furoate, Matching placebo SC + Mometasone Furoate
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Fresno, California • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Results available

A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction

NCT01370356
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline Tartrate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Encino, California • Newport Beach, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2014 · Synced Sep 2, 2026, 4:06 PM EDT
Terminated Phase 3 Interventional Results available

Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease

NCT00436748
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease, Kidney Disease
Interventions
Darbepoetin Alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Year to 18 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
42
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

NCT04472598
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
Placebo for Navitoclax, Ruxolitinib, Navitoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
35
States / cities
Springdale, Arkansas • Fullerton, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

NCT02162849
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Varenicline, Nicotine Patch, Placebo Patch, Placebo Tablet, Questionnaires, Counseling Sessions, Lab Session, Saliva Test
Drug · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

NCT01595516
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
Nebivolol, Metoprolol, Placebo, Bradykinin, Saline, Vitamin C
Drug · Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
45 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 2, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

NCT00859898
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
64
States / cities
Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Sep 2, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

NCT04564339
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy
Interventions
Ravulizumab, Placebo, Background Therapy
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
San Dimas, California • Santa Monica, California • South Gate, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 2, 2026, 4:06 PM EDT